Angiotensin receptor blockers for heart failure

Heart Failure

Volumn , Issue , 2004, Pages 277-318

  Cleland, John G F ^a   Nikitin, Nikolay ^a   Ghosh, Justin ^a   Coletta, Alison P ^a   Memon, Anwar ^a   Clark, Andrew ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 44649094136     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (119)

1. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lendholm LH, Nieminen MS, Omuik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:995-1003.
2. Bloom BS. Continuation of anti-hypertensive medication after 1 year of therapy. Clin Ther 1998; 20:671-681.
3. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, De Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omuik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized study against atenolol. Lancet 2002; 359: 1004-1010.
4. Freemantle N, Cleland JGF, Young S, Mason J, Harrison J. Beta blockade after myocardial infarction:systematic review and meta regression analysis. Br Med J 1999; 318:1730-1737.
5. Mason J, Young P, Freemantle N, Hobbs FDR. Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction. Br Med J 2000; 321(7269):1113-1116.
6. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnson CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ. Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348(7):583-592.
7. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic (ALLHAT). JAMA 2002; 288: 2981-2997.
8. Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Van Gilst WH, Widimsky J. for the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology Freemantle N, Eastaugh J, Mason J, Eds. The Euro heart failure survey programme: survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J, 2003.
9. Cleland JGF, Cohen-Solal A, Cosin-Aguilar J, Dietz R, Eastaugh J, Follath F, Freemantle N, Gavazzi A, Hobbs FDR, Korewicki J, Madeira HC, Preda I, Swedberg K, van Gilst W, Widimsky J. for the IMPROVEMENT of Heart Failure Programme Committees and Investigators and the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. An international survey of the management of heart failure in primary care. The IMPROVEMENT of heart failure programme. Lancet 2002; 360: 1631-1639.
10. Banerjee P, Banerjee T, Khand A, Clark AL, Cleland JGF. Diastolic heart failure - neglected or misdiagnosed? J Am Coll Cardiol 2002; 39(1):138-141.
11. Cleland JGF, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M, O’Mahony D, Polonski L, Taylor J. on behalf of the PEP-CHF investigators. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. Eur J Heart Fail 1999; 1:211-217.
12. Cleland JGF. ACE inhibitors for ‘diastolic’ heart failure? Reasons not to jump to premature conclusions about the efficacy of ACE inhibitors among older patients with heart failure. Eur J Heart Fail 2001; 3:637-639.
13. Nikitin NP, Witte KKA, Clark AL, Cleland JGF. Color tissue Doppler-derived long-axis left ventricular function in heart failure with preserved global systolic function. Am J Cardiol 2003; 90:1174-1177.
14. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. on behalf of the ELITE study group. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE). The Lancet 1997; 349:747-752.
15. Pitt B, Poole Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. on behalf of the ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the losartan heart failure survival study ELITE II. Lancet 2000; 355(May 6):1582-1587.
16. McKelvie RS, Yusuf S, Pericak D, Math M, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J. Comparison of candesartan, enalapril and their combination in congestive heart failure. Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) Pilot Study. Circulation 1999; 100(10): 1056-1064.
17. Cohn JN, Tognoni G. for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. N Engl J Med 2001; 345(23):1667-1675.
18. Cohn JN, Tognoni G, Glazer RD, Spormann D. Baseline demographics of the valsartan heart failure trial. Eur J Heart Fail 2000; 2:439-446.
19. Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-776.
20. McMurray J, Ostergren J, Pfeffer M, Swedberg K, Granger C, Yusuf S, Held P, Michelson E, Olofsson B. on behalf of the CHARM committees and investigators. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM) programme. Eur J Heart Fail 2003; 5:261-270.
21. McMurray JJV, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771.
22. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Ostergren J, Yusuf S. for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure; the CHARM-Overall programme. Lancet 2003; 362:759-766.
23. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Ostergren J. for the CHARM Investigators and Committees. Effects of candesar-tan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362:771-781.
24. Sharma D, Buyse M, Pitt B, Rucinska EJ. and the Losartan Heart Failure Morbidity Metaanalysis Study Group. Meta-analysis of observed mortality data from all controlled, doubleblind multiple-dose studies of losartan in heart failure. Am J Cardiol 2000; 85:187-192.
25. Erdmann E, George M, Voet B, Belcher G, Kolb D, Hiemstra S, Pietrek M, Held P. The safety and tolerability of candesartan cilexetil in CHF. JRAAS 2000; 1(Supplement 1):31-36.
26. Dickstein K, Kjekshus J. and the OPTIMAAL steering committee for the OPTIMAAL study group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet 2002; 360:752-760.
27. Dickstein K, Kjekshus J. for the OPTIMAAL trial steering committee and investigators. comparison of baseline data, initial course and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). Am J Cardiol 2001; 87:766-771.
28. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van De Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906.
29. Velazquez EJ, Pfeffer MA, McMurray JJV, Maggioni AP, Rouleau JL, Van De Werf F, Kober L, White HD, Swedberg K, Leimberger JD, Gallo P, Sellers MA, Edwards S, Henis M, Califf RM. Valsartan in acute myocardial infarction (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail 2003; 5:537-544.
30. Cleland JGF, Witte K, Thackray S. Bradykinin and ventricular function. Eur Heart J 2000; Suppl H(2):H20-H29.
31. Zusman RM. Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biological activity. Am J Kidney Dis 1987; 10:13-23.
32. Cleland JGF, Dargie HJ, Hodsman GP, Ball SG, Robertson JI, Morton JJ, East BW, Robertson I, Murray GD, Gillen G. Captopril in heart failure. A double blind controlled trial. Br Heart J 1984; 52(530):535.
33. Cleland JGF, Semple P, Hodsman GP, Ball SG, Ford I, Dargie HJ. Angiotensin II levels, hemodynamics and sympathoadrenal function after low-dose captopril in heart failure. Am J Med 1984; 77:880-886.
34. Cleland JGF, Dargie HJ, Ball SG, Gillen G, Hodsman GP, Morton JJ, East BW, Robertson I, Ford I, Robertson JL. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones and metabolic state. Br Heart J 1985; 54: 305-312.
35. Cleland JGF, Dargie HJ, McAlpine H, Ball SG, Morton JJ, Robertson JL, Ford I. Severe hypotension after first dose of enalapril in heart failure. Br Med J 1985; 291:1309-1312.
36. Cleland JGF, Dargie HJ, East BW, Robertson I, Hodsman GP, Ball SG, Gillen G, Robertson JI, Morton JJ. Total body and serum electrolyte composition in heart failure: the effects of captopril. Eur Heart J 1985; 6:681-688.
37. Cleland JGF, Dargie HJ. Heart failure, renal function, and angiotensin converting enzyme inhibitors. Kidney Int 1987; 31:S220-S228.
38. Cleland JGF, Gillen G, Dargie HJ. The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure. Eur Heart J 1988; 9(2):132-141.
39. Cleland JGF, Krikler D. Modification of atherosclerosis by agents that do not lower cholesterol. Br Heart J 1993; 69:54-62.
40. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90:2056-2069.
41. Minisi AJ, Thames MD. Distribution of left ventricular sympathetic afferents demonstrated by reflex responses to transmural myocardial ischemia and to intracoronary and epicardial bradykinin. Circulation 1993; 87:240-246.
42. Morgan K, Wharton J, Webb JC, Keogh BE, Smith PLC, Taylor KM, Oakley CM, Polak JM, Cleland JGF. Co-expression of renin-angiotensin system component genes in human atrial tissue. Journal of Hypertension 1994; 12(suppl 4):S11-S19.
43. Cleland JGF, Cowburn PJ, Morgan K. Neuroendocrine activation after myocardial infarction: causes and consequences. Heart 1996; 76(suppl 3):53-59.
44. Johnston CI, Risvanis J. Preclinical pharmacology of angiotensin II receptor antagonists. Am J Hypertens 1997; 10:306S-310S.
45. Smith RD, Timmermans C. Human angiotensin receptor subtypes. Curr Opinion Nephrol Hypertens 1994; 3:112-122.
46. Timmermans PBM, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD. Angiotensin II receptors and functional correlates. Am J Hypertens 1992; 5:2215-2355.
47. Asano K, Dutcher DL, Port JD, Minobe WA, Tremmel KD, Roden RL, Bohlmeyer TJ, Bush EW, Jenkin MJ, Abraham WT, Raynolds MV, Zisman LS, Bristow MR, Perryman MB. Selective downregulation of the angiotensin II AT-1-receptor subtype in failing human ventricular myocardium. Circulation 1997; 95:1193-1200.
48. Haywood GA, Gullestad L, Katsuya T, Hutchinson HG, Pratt RE, Horiuchi M, Fowler MB. AT-1 and AT-2 angiotensin receptor gene expression in human heart failure. Circulation 1997; 95:1201-1206.
49. Regitz-Zagrosek V, Friedel N, Heymann A, Bauer P, Neuss M, Rolfs A, Steffen C, Hildebrandt A, Fleck E. Regulation of the angiotensin receptor subtypes in cell cultures, animal models and human diseases. Circulation 1995; 91:1461-1471.
50. Stoll M, Stecklings UM, Paul M, Bottari SP, Metzeger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95:651-657.
51. Yamada T, Akishita M, Pollman MJ, Gibbons GH, Dzau VJ, Horiuchi M. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type I receptor action: an in vitro gene transfer study. Life Sci 1998; 63:PL289-PL295.
52. Pitt B. ‘Escape’ of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. Cardiovasc Drugs Ther 1995; 9(1):145-149.
53. MacFadyen RJ, Lee AFC, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?. Heart 1999; 82(1):57-61.
54. Struthers AD, Anderson G, MacFadyen RJ, Fraser C, MacDonald TM. Non-adherence with ACE inhibitor treatment is common in heart failure and can be detected by routine serum ACE activity assays. Heart 1999; 82:584-588.
55. Teo K, Yusuf S, Pfeffer M, Kober L, Hall A, Pogue J, Latini R, Collins R. for the ACE Inhibitors Collaborative Group. Effects of long-term treatment with angiotensin-convertingenzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002; 360:1037-1043.
56. Cleland JGF, Bulpitt CJ, Falk RH, Findlay IN, Oakley CM, Murray G, Poole-Wilson PA, Prentice CRM, Sutton GC. Is aspirin safe for patients with heart failure? Br Heart J 1995; 74(3):215-219.
57. Cleland JGF, John J, Houghton T. Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?. Curr Opin Nephrol Hypertens 2001; 10: 625-631.
58. Cleland JGF. No reduction in cardiovascular risk with NSAIDs-including aspirin? Lancet 2002; 359(9301):92-93.
59. Cleland JGF. For Debate: Preventing atherosclerotic events with aspirin. Br Med J 2002; 324(7329):103-105.
60. Cleland JGF. Is aspirin ‘the weakest link’ in cardiovascular prophylaxis. The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis 2002; 44:275-292.
61. Cleland JGF. Anticoagulant and antiplatelet therapy in heart failure. Curr Opinion Cardiol 1997; 12:276-287.
62. Herrlin B, Nyquist O, Sylven C. Induction of a reduction in haemoglobin concentration by enalapril in stable, moderate heart failure: A double blind study. Br Heart J 1991; 66(3): 199-205.
63. Belcher G, Hubner R, George M, Elmfeldt D, Lunde H. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997; 11(suppl 2):S-85-S-89.
64. Brooksby P, Robinson PJ, Segal R, Klinger G, Pitt B, Cowley AJ. Effects of losartan and captopril on QT-dispersion in elderly patients with heart failure. ELITE study group. Lancet 1999; 354:395-396.
65. Binkley PF, Haas GJ, Starling RC, Nunziata E, Hatton PA, Leier C, Cody RJ. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J An Cell Cardiol 1993; 21:655-661.
66. Binkley PF, Nunziata E, Leier CV. Selective AT-1 blockade with losartan does not restore autonomic balance in patients with heart failure. J Am Coll Cardiol 1998; 31(suppl A):250A.
67. Wurzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, Burnier M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2001; 19:1855-1860.
68. Puig JG, Torres R, Ruilope LM. AT1 blockers and uric acid metabolism: are there relevant differences? J Hypertens 2002; 20(suppl 5):S29-S31.
69. Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, Stevenson JC, Coats AJS. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 18:858-865.
70. Crozier I, Ikram H, Awan N, Cleland JGF, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, Rucinska E. Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995; 91:691-697.
71. Pitt B, Dickstein K, Benedict C, Packer R, Willenheimer R, Murali S, Denlay MC, Change PI, Grossman W for the RAAS Investigators. The randomized angiotensin receptor antagonist - ACE inhibitor study (RAAS) - pilot study. Circulation 1996; 94(suppl):I-428.
72. Packer M, Poole Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie B, Ryden L, Thygesen K, Uretsky B. on behalf of the ATLAS investigators. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100:2312-2-318.
73. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998; 19:481-489.
74. Cleland JGF, Poole Wilson PA. ACE inhibitors for heart failure: a question of dose. Br Heart J 1994; 72:106-110.
75. Maggioni A, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN. for the Valsartan Heart Failure Trial Investigators. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin converting enzyme inhibitors. J Am Coll Cardiol 2002; 40:1414-1421.
76. Klinge R, Polis A, Dickstein K, Hall C. Effects of angiotensin II receptor blockade on N-terminal proatrial natriuretic factor plasma levels in chronic heart failure. J Cardiac Fail 1997; 3:75-81.
77. Riegger GAJ, Bouzo H, Petr P, Munz J, Spacek R, Pethig H, von Brehen V, George M, Arens H-J. for the STRETCH Investigators. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation 1999; 100: 2224-2230.
78. Bart BA, Ertl G, Held P, Kuch J, Maggioni AP, McMurray J, Michelson EL, Rouleau JL, Warner-Stevenson L, Swedberg K, Young JB, Yusuf S, Sellers MA, Granger CB, Califf RM, Pfeffer MA. Contemporary management of patients with left ventricular systolic dysfunction. Results from the study of patients intolerant of converting enzyme inhibitors (SPICE) registry. Eur Heart J 1999; 20(16):1182-1190.
79. Matsumori A. Assessment of Response to Candesartan in Heart Failure in Japan (ARCH-J) Study Investigators. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Failure 2003; 5:669-77.
80. Cleland JGF, Freemantle N, Kaye GC, Nasir M, Velavan P, Lalukota K, Mudawi T, Shelton R, Clark AL, Coletta AP. Clinical trials update from the American Heart Association: omega-3 fatty acids and arrhythmia risk in patients with an implantable defibrillators, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PAD and DEFINITE. Eur J Heart Fail 2004; 6:109-15.
81. Coletta AP, Cleland JGF, Freemantle N, Loh H, Memon A, Clark AL. Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM. Eur J Heart Fail 2003; 5:697-704.
82. Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, Olofsson B, Ostergren J, Yusuf S. for the CHARM-Programmed Investigators. Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail 1999; 5(3):276-282.
83. Yusuf S, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure the SOLVD Investigators. New Engl J Med 1991; 325: 293-302.
84. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-con-verting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. New Engl J Med 2000; 342:145-153.
85. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
86. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN. for the Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-HeFT). Circulation 2003; 107:1278-1283.
87. Carson P, Tognoni G, Cohn JN. Effect of valsartan on hospitalization: results from ValHeFT. J Card Fail 2003; 9:164-171.
88. Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PHJM, Holwerda NJ, Tognoni G, Cohn JN. for the Val-HeFT Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the valsartan heart failure trial (Val-HeFT). Circulation 2002; 106:2454-2458.
89. Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, Benza R, Gottlieb SO, Kleemann TD, Rosconi F, Vandervoort PM, Cohn JN. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002; 40(5):970-975.
90. Cohn JN, Tognoni G, Glazer RD, Spormann D, Hester A. Rationale and design of the valsartan heart failure trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999; 5:155-160.
91. Pfeffer MA, McMurray JJV, Velazquex EJ, Rouleau JL, Kobel L, Maggioni HP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartain in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Eng J Med 2003; 349:1893-1906.
92. Velazquez EJ, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau JL, Van de Werf F, Kober L, White HD, Swedberg K, Leimberger JD, Gallo P, Sellers MA, Edwards S, Henis M, Califf RM; VALIANT Investigators. Related Article Links VALSartan In Acute myocardial iNfarCtion (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail 2003 Aug; 5(4): 537-44.
93. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. The randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000; 101:378-384.
94. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design and baseline characteristics of patients in the losartan heart failure survival study-ELITE II. J Card Fail 1999; 5:146-154.
95. Konstam M, Patten RD, Thomas I, Ramahi T, La Bresh K, Goldman S, Lewis W, Gradman A, Self KS, Bittner V, Rand W, Kinan D, Smith JJ, Ford T, Segal R, Udelson JE. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure; results of the ELITE ventricular function substudy. Am Heart J 2000; 139(6):1081-1087.
96. Cowley AJ, Wiens BL, Segal R, Rich MW, Santanello NC, Dasbach EJ, Pitt B. ELITE Investigators. Randomised comparison of losartan vs captopril on quality of life in elderly patients with symptomatic heart failure: the losartan heart failure ELITE quality of life substudy. Qual Life Res 2000; 9(4):377-384.
97. Teo KK, Yusuf S, Pfeffer M, Torp-Pedersen C, Kober L, Hall A, Pogue J, Latini R, Collins R. ACE inhibitors Collaborative Group. Effects of long-term treatment with ACE inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002; 360:1037-1043.
98. Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, Stevenson LW, Swedberg K, Young J, Yusuf S, Califf RM, Bart BA, Held P, Michelson EL, Sellers MA, Ohlin G, Spara-pani R, Pfeffer MA. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J 2000; 139(4):609-617.
99. Dickstein K, Chang P, Willenheimer R, Haunso S, Remes J, Hall C, Kjekshus J. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995; 26(2):438-445.
100. Lang RM, Elkayam U, Yellen LG, Krauss D, McKelvie RS, Vaughan DE, Ney DE, Makris L, Chang PI. on behalf of the Losartan Pilot Exercise Study Investigators. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. J Am Coll Cardiol 1997; 30:983-991.
101. Yusuf S. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl J Med 1991; 325:293-302.
102. Eccles M, Freemantle N, Mason JM. for the North of England Evidence Based Guideline Development Project. Evidence based clinical practice guideline: ACE inhibitors in the primary care management of adults with symptomatic heart failure. Br Med J 1998; 316:1369-1375.
103. Os I, Bratland B, Dahlof B, Gisholt K, Syvertsen JO, Tretli S. Female sex as an important determinant of lisinopril-induced cough. Lancet 1992; 339:303-310.
104. Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis IIIPW, Young JB, Probstfield J. Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD). Am Heart J 1996; 131:350-355.
105. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117:234-242.
106. Malini PL, Strocchi E, Zanardi M, Milani M, Ambrosioni E. Thromboxane antagonism and cough induced by angiotensin-converting enzyme inhibitor. Lancet 1997; 350:15-18.
107. Cleland JGF. Lack of effect of nedocromil sodium in ACE inhibitor-induced cough. Lancet 1995; 345:394.
108. Hargreaves MR, Benson MK. Inhaled sodium cromoglycate in angiotensin converting enzyme inhibitor induced cough. Lancet 1995; 345:13-16.
109. Schulman G, Hakim R, Arias R, Silverberg M, Kaplan AP, Arbeit L. Bradykinin generation by dialysis membranes: possible role in anaphylactic reaction. J Am Soc Nephrol 1993; 3: 1563-1569.
110. Gottleib SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M. Hemodynamic and neurohormonal effects of the angiotensin II antagonist Losartan in patients with congestive heart failure. Circulation 1993; 88:1602-1609.
111. Cleland J, Semple P, Hodsman P, Ball S, Ford I, Dargie H. Angiotensin II levels, hemodynamics, and sympathoadrenal function after low dose captopril in heart failure. Am J Med 1984; 77: 880-886.
112. Kostis J, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D. Tolerability of enalapril by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction. Am Heart J 1994; 128:358-364.
113. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. for the CALM Study Group. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BrMed J 2000; 321(7274):1440-1444.
114. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Poke MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Related Articles, Links Renoprotective effect of the an-geotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20; 345(12):851-60.
115. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Related Articles, Links effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med Sep 20; 345(12):861-9.
116. Havranek EP, Thomas I, Smith WB, Ponce GA, Bilsker M, Munger MA, Wolf RA. Dose-related beneficial long-term hemodynamic and clinical efficacy of Irbesartan in heart failure. J Am Coll Cardiol 1999; 33(5):1174-1181.
117. Elmfeldt D, George M, Hubner R, Olofsson B. Candesartan cilexetil, anew generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; 11(suppl 2):S49-S53.
118. Guazzi M, Melzi G, Agostoni P. Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997; 80:1572-1576.
119. Warner JGJ, Metzger DC, Kitzman DW, Wesley DJ, Little WC. Losartan improves exercise tolerance and quality of life in patients with diastolic dysfunction. J Am Coll Cardiol 1999; 33: 1567-1572.